Clinical Trial: CD103⁺CD8⁺/CD8⁺ T cell ratio in pleural effusion for predicting immunotherapy efficacy in advanced non-small cell lung cancer: a prospective multicenter cohort study (China)

Posted On: 2026-08-17

China, Aug. 17 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'CD103⁺CD8⁺/CD8⁺ T cell ratio in pleural effusion for predicting immunotherapy efficacy in advanced non-small cell lung cancer: a prospective multicenter cohort study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130085

Registration Time: 2026/08/14

Type: Observational study

Primary Sponsor: West China Hospital, Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=318324

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: CD103⁺CD8⁺/CD8⁺ T cell ratio in pleural effusion for predicting immunotherapy efficacy in advanced non-small cell lung cancer: a prospective multicenter cohort study (China)